Procter & Gamble Co vs Synopsys, Inc. — how do they compare? Procter & Gamble Co trades at $149.97 (market cap $349.77B), while Synopsys, Inc. trades at $503.05 (market cap $95.39B). The key difference: Procter & Gamble Co is far larger — about 3.7× Synopsys, Inc.'s market cap, and Procter & Gamble Co pays a 2.89% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Synopsys, Inc. for 71 Days on average.
| PG | SNPS | |
|---|---|---|
Market Cap | $349.77B | $95.39B |
Volume | 10,055,825 | 3,374,903 |
Sector | Consumer Staples | Technology |
52-Week High | $167.18 | $534.56 |
52-Week Low | $138.10 | $367.70 |
Typical Hold Time | 131 Days | 71 Days |
Enterprise Value | $375.61B | $102.62B |
Dividend Yield | 2.89% | — |
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, showing resilience amid market volatility. The stock maintains a bullish technical signal with strong moving average support and has consistently beaten earnings estimates in recent quarters. PG demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and steady dividend payments, though valuation multiples remain elevated versus peers.
PG offers stable growth with dividend reliability but faces premium valuation concerns. The 8.3% upside to consensus target of $160.13 suggests moderate potential, while competitive pressures and soft demand outlook present headwinds. Institutional ownership trends show mixed positioning, requiring careful monitoring of margin sustainability and consumer spending patterns.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, but maintains strong bullish momentum with recent AI-driven partnerships and earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5%, supported by a 72.38% gross margin. Technical indicators show bullish moving averages but overbought RSI levels above 89, with key support at $500 and resistance at $505. Recent announcements with OpenAI and Amazon have driven significant investor optimism and price target upgrades.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus target suggesting 14% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks include high valuation (P/E 87.7) and execution challenges in large-scale partnerships. The stock's proximity to all-time highs requires careful monitoring of earnings delivery and competitive pressures in the EDA market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →